Oncolytics reports Q3 EPS (8c), consensus (8c)

As of September 30, the Company reported $40.0M in cash and cash equivalents, with a projected cash runway for at least 12 months. “We continue to build our case for pelareorep to be an important immunotherapy in multiple large and in-need cancer indications,” said Dr. Matt Coffey, President and CEO. “The ESMO presentations show the first batch of survival data from first-line metastatic pancreatic cancer patients exceeds the historical averages recorded in control trials, aligning with the positive response data we first reported at SITC last year. They also reveal that pelareorep can generate an immune response in heavily pre-treated metastatic colorectal cancer patients. I’m pleased to note that GOBLET has now reported consecutive indications where pelareorep-based therapy has met the success criteria for efficacy, validating our decision to explore pelareorep in gastrointestinal indications in combination with the checkpoint inhibitor atezolizumab. The compelling GOBLET results were instrumental in obtaining a $5M grant from PanCAN to explore pelareorep in combination with modified FOLFIRINOX with and without atezolizumab in pancreatic cancer patients.”